Abstract:Background Lupus nephritis is one of the most common and severe complications of SLE affecting more than 60% patients. The management of lupus nephritis largely depends on renal histopathologic findings. Due to the invasive feature and complications of renal biopsy, it is significantly urgent to develop novel biomarkers to predict renal pathology. Methods In this cross-sectional study, a total of 77 biopsy-proven active LN, 61 active SLE without LN75 inactive SLE patientsand 28 age and gender matched healthy controls were recruited. Urinary levels of activated leukocyte cell adhesion molecule (ALCAM) were determined by enzyme-linked immunosorbent assay in urine samples of the above-mentioned subjects. Renal histopathology was review by an experienced renal pathologist. Urinary ALCAM levels were normalized by urine creatinine. For active LN patients, all samples were collected at the time of renal biopsy. Results Urinary ALCAM levels were significantly increased in active LN patients when compared to those in active SLE without renal involvement patients, inactive SLE patients, and healthy controls (figure 1A). ROC analysis showed a good performance of urinary ALCAM in discriminating active LN from active SLE without renal involvementinactive SLEand healthy controls (figure 1B). Further correlation analysis revealed a positive correlation between urinary ALCAM and general disease activity-SLEDAI score, as well as renal disease activity-rSLEDAI and SLICC-RAS (figure 2A-C). Urinary ALCAM also correlated with lab parameters including 24 hour urine protein, hemoglobin, and complement 3 (C3) (Figure 2D-F). More interestingly, we found a good prediction value of urinary ALCAM in renal histopathological findings. Urinary ALCAM levels were significantly increased in proliferative LN (Type III and IV) as compared to those in membranous LN Type V (Figure 3). It outperformed conventional biomarkers (anti-dsDNA antibody, C3, C4) in discriminating the two different types of LN. Urinary ALCAM levels correlated positively with activity index (AI) in renal histopathology, indicating a role in guiding clinical management of LN.Abstract 164 Figure 1 Urinay ALCAM levels were elevated in active LN patients. (A) Group comparison showed significant increase of urinary ALCAM in active LN patients (14 IQR (6.97-24.8) ng/mg) when compared to those in active SLE without renal involvement patients (3.54 IQR (1.31-7.58) ng/mg), inactive SLE patients (2.75 IQR (1.45-5.67) ng/mg), and healthy controls (1.29 IQR (0.665-1.89) ng/mg). (B) Receiver Operating Characteristic (ROC) curve analysis indicated a good performance of urinary ALCAM in discriminating active LN from active SLE without renal involvement, inactive SLE, and healthy controls. Group Description: A=Active LN group; N=Active SLE without renal involvement group; C=Inactive SLE group; H=healthy control groupAbstract 164 Figure 2 Correlation between urinary ALCAM and (A) rSLEDAI, (B) SLEDAI, (C) SLICC RAS, (D) 24 hour urine protein level, (E) hemoglobin, and (F) complement 3 level. rSLEDAI = renal SLEDAI, SLICC RAS = SLICC renal activity score, Hb = hemoglobin. C3 = complement 3Abstract 164 Figure 3 Urinary ALCAM levels were elevated in proliferative LN patients. (A) Group comparison between proliferative (Class III and Class IV) LN patients (16.3 IQR (8.01-28.5) ng/mg) and membranous patients (Class V LN) (4.47 IQR (2.63-6.54) ng/mg). (B) Receiver Operating Characteristic (ROC) curve analysis indicated a good discriminative performance of urinary ALCAM in proliferative LN versus membranous LNAbstract 164 Figure 4 Correlation analysis between urinary ALCAM and renal pathology. (A) Urinary ALCAM correlated positively with activity index (AI) in renal pathology. (B) Urinary ALCAM didn't correlate with chronicity index (CI) in renal pathologyAbstract 164 Table 1 Demographic characteristics of study subjectsAbstract 164 Table 2 Conclusions Urinary ALCAM is a promising biomarker for predicting renal histopathological changes in LN, which may serve as a valuable surrogate of renal biopsy. These findings should be confirmed in a larger cohort to further validate the utility of urinary ALCAM as a biomarker. Funding Source(s): N/A

The Utility of Urinary Biomarker Panel in Predicting Renal Pathology and Treatment Response in Chinese Lupus Nephritis Patients.

Early-stage predictors for treatment responses in patients with active lupus nephritis.

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts

Urinary Immune Complexes Reflect Renal Pathology in Lupus Nephritis

Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis

Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis

Urine L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multi-ethnicity

Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis

Composite Urinary Biomarkers to Predict Pathological Tubulointerstitial Lesions in Lupus Nephritis.

Combined Detection of Umcp-1 and Utweak for Rapid Discrimination of Severe Lupus Nephritis.

Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology

164 Urinary ALCAM As a Novel Biomarker for Renal Pathology in Lupus Nephritis

Investigating the value of urinary biomarkers in relation to lupus nephritis histopathology: present insights and future prospects

Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis

Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis

Urinary Biomarkers Associated With Pathogenic Pathways Reflecting Histologic Findings in Lupus Nephritis